Foreword.
Keynote Addresses. (H. Varmus, J. Henney) Toward a structured
national program to speed the invention and development of new
technologies for measuring the progression of chronic diseases
(J.F. Niblack).
Biomarkers and Surrogate Endpoints in Clinical Research:
Definitions and Conceptual Model. Plenary Sessions. Plenary Session
1: Historical Perspectives.
Biomarkers as surrogate endpoints in clinical trials for HIV/AIDS:
A model for other diseases? D. Mildvan). Biomarkers for HIV/AIDS:
challenges ahead (J.M. Kagan). Biomarkers as Surrogates in Clinical
Research (S.L. Zeger).
Plenary Session 2: The Need and Prospects for Biomarkers in
Therapeutic Development.
Contribution of pharmacology markers (P. Rolan). The importance of
markers in drug discovery and development (M.B. Silber).
Prospective search for AD biomarkers (T. Sunderland). Use of modern
proteomics to discover protein biomarkers of disease (R. Parekh).
The early detection cancer research network (R.D. Klausner).
Plenary Session 3: Opportunities for Developing Biomarkers for
Central Nervous System Disorders.
Biomarkers for the experimental therapeutics of Huntington's
disease and Parkinson's disease (I. Shoulson). Imaging the addicted
brain (N.D. Volkow). Cognitive biomarkers and the treatment of
schizophrenia (B.A. Cornblatt). Genetic and epidemiologic basis for
developing biomarkers of complex diseases (K.R. Merikangas).
Plenary Session 4: Immune and Inflammatory Markers.
Introduction and Overview. (A. Fauci). Immune memory and protective
immunity (R. Ahmed). Seeing is believing: monitoring in vivo gene
expression by magnetic resonance imaging (T.J. Meade). Gene
expression in inflammatory disease using multiple DNA array
technologies (D.H. Mack). Challenges in discovery of useful
biomarkers (G. Ringold).
Plenary Session 5: Emerging Technologies: Insight Into Novel
Biomarkers.
From ambiguities to insights (D.J. Lipman). Emergent order in
systematic genome-scale observations in variation in gene
expression patterns and its implication for diagnosis and
surveillance (P.O. Brown). cDNA approaches to analysis of human
disease (J.H. Eberwine). SAGE and expression technologies-potential
biomarker applications (G. Riggins).
Breakout Sessions.
Neurosciences I - Neurodegenerative and Neuropsychiatric Disorders
(I. Shoulson, L.S. Brady). Neurosciences II - Biomarkers for
Alcohol and Drug Abuse (E.D. London, F. Vocci). Neurosciences III -
Biomarkers for Pain Assessment (G. Fischbach, H. Slavkin, C. Kitt).
Biomarkers for Chronic Lung Diseases (S. Buist). Pharmacokinetic
and Pharmacodynamic Methods in Biomarker Development and
Application (S.C. Piscitelli, C.C. Peck). Biomarkers of Toxicity
and Surrogate Endpoints for Safety (F.D. Sistare, J.D. Morrow, P.
Clax). Biomarkers in Cardiovascular Diseases (G. Sopko, L.
Friedman). Cardiovascular I - Acute Ischemic Coronary Syndromes (J.
Hochman, V. Dzau). Cardiovascular II - Stable Cardiovascular
Disease (R. Califf, R.S. Balaban). Biomarkers for Transplantation
(W. Harmon et al.). Cancer Prevention - Biomarkers and Surrogate
Endpoints in Clinical Trials (E.R. Greenberg, W. Ki Hong).
Biomarkers in Cancer Therapeutics (A.F. LoBuglio, J.M. Pluda, P.
Ivy). Biomarkers of Severe Infections and Septic Shock (T.R.
Martin, A.F. Suffredini). Biomarkers in the Spectrum of Autoimmune
Diseases (D.S. Pisetsky, E. Collier). Biomarkers of Osteoporosis
(S.R. Cummings, S. Sherman, J. McGowan). Biomarkers of Joint
Destruction and Repair (K.D. Brandt, S. Serrate-Sztein).
Establishing the Research Infrastructure to Develop and Classify
Ask a Question About this Product More... |